Groundbreaking Results from Avidity's FORTITUDE™ Trial Display Exceptional Progress in Gene Reduction and Functional Enhancement
Wednesday, 12 June 2024, 08:28
Exciting Outcomes Unveiled
Avidity's AOC 1020 data from the Phase 1/2 FORTITUDE™ Trial exhibit a groundbreaking development - a notable decrease surpassing 50% in DUX4 regulated genes.
Positive Functional Indicators
The trial also reveals promising trends towards functional improvement, implying a potential paradigm shift in addressing gene-related challenges.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.